Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside in COVID-19 with AKI
NCT04818216Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Jun 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nicotinamide riboside in acute kidney injury (AKI), sponsored by UT Health San Antonio. Started Jun 2021; status: completed.
02
Drugs
nicotinamide riboside
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04818216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818216.